ストックスクリーナーアプリを入手
0.4608
19.23%
-0.1097
アフターアワーズ：
.46
-0.0008
-0.17%
前日終値:
$0.5705
開ける：
$0.5748
24時間の取引高:
79.51M
Relative Volume:
6.11
時価総額：
$219.53M
収益：
$1.21M
当期純損益:
$-177.12M
株価収益率:
-0.576
EPS:
-0.8
ネットキャッシュフロー:
$-162.37M
1週間 パフォーマンス:
+26.11%
1か月 パフォーマンス:
-34.12%
6か月 パフォーマンス:
-70.65%
1年 パフォーマンス:
-80.80%
1日の値動き範囲:
$0.4501
$0.7072
1週間の範囲:
$0.32
$0.7072
52週間の値動き範囲:
$0.2836
$2.45
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
名前
Lexicon Pharmaceuticals Inc
セクター
電話
(281) 863-3000
住所
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.4608 | 219.53M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 33.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-30 | 開始されました | Leerink Partners | Outperform |
| 2023-03-07 | 開始されました | Jefferies | Hold |
| 2022-08-12 | 開始されました | Piper Sandler | Overweight |
| 2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-01-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-18 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-12-11 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2019-11-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-11 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-07-29 | ダウングレード | Stifel | Buy → Hold |
| 2019-03-25 | アップグレード | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 繰り返されました | Stifel | Buy |
| 2018-02-23 | ダウングレード | Needham | Buy → Hold |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-03-01 | 繰り返されました | Wedbush | Outperform |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-05 | 繰り返されました | Wedbush | Outperform |
| 2016-08-02 | 開始されました | Citigroup | Buy |
| 2016-03-02 | 繰り返されました | Wedbush | Outperform |
| 2015-11-09 | 繰り返されました | Wedbush | Outperform |
| 2015-09-28 | アップグレード | Gabelli & Co | Sell → Hold |
| 2015-09-18 | ダウングレード | Gabelli & Co | Hold → Sell |
| 2015-08-10 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga
The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU.com
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Yahoo Finance
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News
Lexicon (LXRX) Secures $1 Billion Deal with Novo Nordisk for Obe - GuruFocus
Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry - insights.citeline.com
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters
Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa
Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha
Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener
Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
Novo Nordisk in licensing deal with Lexiconcould pay up to $1 billion - MarketScreener
Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump - Marketscreener.com
Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 - Marketscreener.com
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug - Investing.com
Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider.com
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
Chronic Neuropathic Pain Market to Reach New Heights in Growth - openPR
Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50% - simplywall.st
FDA rejects Lexicon's Zynquista for diabetes, kidney disease - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Piper Sandler Cuts Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target to $6.00 - Defense World
Equities Analysts Issue Forecasts for LXRX Q1 Earnings - Defense World
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Brokerages - Defense World
Lexicon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies - TipRanks
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges - TipRanks
LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
What Analysts Are Saying About Lexicon Pharmaceuticals Stock - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth - TipRanks
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com India
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Lexicon: Q4 Earnings Snapshot - KTEN
Lexicon Pharma beats Q4 estimates, shares rise on strong revenue - Investing.com India
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals Inc (LXRX) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):